2025
SJR Q2
JCR Q2 · 2,4
79 eşleşen makale
SCIE
Dergi ayrıntısı
Pharmacology Biochemistry and Behavior
- Yayıncı
- Elsevier Inc.
- Ülke
- United States · Northern America
- Tür
- journal
- ISSN
-
0091305718735177
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 0,75
- Quartile Q2
- H-Index 154
- Atıf/yayın 2,54
- Doküman (3y) 354
- Atıf (3y) 979
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 2,4
- 5Y JIF 3,1
- JCI 0,73
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Behavioral Neuroscience Q3
- Biochemistry Q2
- Biological Psychiatry Q3
- Clinical Biochemistry Q2
- Pharmacology Q2
- Toxicology Q2
Alanlar
- Biochemistry, Genetics and Molecular Biology
- Neuroscience
- Pharmacology, Toxicology and Pharmaceutics
WoS kategorileri
- Behavioral Sciences | Neurosciences | Pharmacology & Pharmacy
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 0,75 | 2,4 | 3,1 | 0,73 | Q2 | 154 |
| 2024 | Q1 | Q2 | 0,952 | 2,5 | 3,1 | 0,83 | Q2 | 150 |
| 2023 | Q1 | Q1 | 1,05 | 3,3 | 3,2 | 0,88 | Q2 | 150 |
| 2022 | Q1 | Q1 | 0,967 | 3,6 | 3,5 | 0,84 | Q2 | 150 |
| 2021 | Q1 | Q2 | 0,859 | 3,7 | 3,4 | 0,79 | Q2 | 150 |
| 2020 | Q1 | Q2 | 1,184 | 3,5 | 3,2 | 0,87 | Q2 | 150 |
| 2019 | Q2 | Q2 | 0,814 | 2,5 | 2,8 | 0,79 | Q2 | 150 |
| 2018 | — | Q2 | — | 2,8 | 2,9 | 0,89 | Q2 | — |
| 2017 | Q1 | Q2 | 1,15 | 2,5 | 2,8 | 0,92 | Q2 | 150 |
| 2016 | Q1 | Q2 | 1,206 | 2,7 | 2,6 | — | — | 150 |
| 2015 | Q1 | Q2 | 1,13 | 2,5 | 2,6 | — | — | 150 |
| 2014 | Q1 | Q2 | 1,149 | 2,8 | 2,8 | — | — | 150 |
| 2013 | Q1 | Q2 | 1,281 | 2,8 | 2,8 | — | — | 150 |
| 2012 | Q1 | Q2 | 1,197 | 2,6 | 2,8 | — | — | 150 |
| 2011 | Q1 | Q2 | 1,138 | 2,5 | 2,8 | — | — | 150 |
| 2010 | Q1 | Q2 | 1,32 | 2,6 | 2,7 | — | — | 150 |
| 2009 | — | Q2 | — | 3 | 2,7 | — | — | — |
| 2008 | — | Q2 | — | 2,8 | 2,7 | — | — | — |
| 2007 | — | Q2 | — | 2,4 | 2,6 | — | — | — |
| 2006 | — | Q2 | — | 2,1 | — | — | — | — |
| 2005 | — | Q2 | — | 2 | — | — | — | — |
| 2004 | — | Q2 | — | 2,5 | — | — | — | — |
| 2003 | — | Q2 | — | 2,3 | — | — | — | — |
| 2002 | — | Q2 | — | 1,7 | — | — | — | — |
| 2001 | — | Q2 | — | 1,7 | — | — | — | — |
| 2000 | — | Q2 | — | 1,7 | — | — | — | — |
| 1999 | — | Q2 | — | 1,8 | — | — | — | — |
| 1998 | — | Q2 | — | 1,6 | — | — | — | — |
| 1997 | — | Q2 | — | 1,5 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | BEHAVIORAL SCIENCES | SCIE | Q2 | Q3 | 24/57 |
| 2025 | NEUROSCIENCES | SCIE | Q3 | Q3 | 225/330 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 215/356 |
| 2024 | BEHAVIORAL SCIENCES | SCIE | Q2 | Q2 | 18/57 |
| 2024 | NEUROSCIENCES | SCIE | Q3 | Q2 | 192/314 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 181/352 |
| 2023 | BEHAVIORAL SCIENCES | SCIE | Q1 | Q2 | 8/55 |
| 2023 | NEUROSCIENCES | SCIE | Q2 | Q2 | 124/310 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 119/354 |
| 2022 | BEHAVIORAL SCIENCES | SCIE | Q1 | Q2 | 10/52 |
| 2022 | NEUROSCIENCES | SCIE | Q2 | Q2 | 120/272 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 114/278 |
| 2021 | BEHAVIORAL SCIENCES | SCIE | Q2 | Q3 | 15/53 |
| 2021 | NEUROSCIENCES | SCIE | Q3 | Q2 | 150/275 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 133/279 |
| 2020 | BEHAVIORAL SCIENCES | SCIE | Q2 | Q2 | 14/53 |
| 2020 | NEUROSCIENCES | SCIE | Q3 | Q2 | 145/273 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 133/276 |
| 2019 | BEHAVIORAL SCIENCES | SCIE | Q2 | Q3 | 22/53 |
| 2019 | NEUROSCIENCES | SCIE | Q3 | Q3 | 180/272 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 153/271 |
| 2018 | BEHAVIORAL SCIENCES | SCIE | Q2 | Q2 | 15/53 |
| 2018 | NEUROSCIENCES | SCIE | Q3 | Q2 | 147/267 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 118/267 |
| 2017 | BEHAVIORAL SCIENCES | SCIE | Q2 | Q3 | 23/51 |
| 2017 | NEUROSCIENCES | SCIE | Q3 | Q2 | 165/261 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 128/261 |
| 2016 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 18/51 |
| 2016 | NEUROSCIENCES | SCIE | Q3 | — | 133/259 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 110/257 |
| 2015 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 20/51 |
| 2015 | NEUROSCIENCES | SCIE | Q3 | — | 144/256 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 108/255 |
| 2014 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 20/51 |
| 2014 | NEUROSCIENCES | SCIE | Q3 | — | 127/252 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 97/255 |
| 2013 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 24/49 |
| 2013 | NEUROSCIENCES | SCIE | Q3 | — | 136/252 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 92/256 |
| 2012 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 26/49 |
| 2012 | NEUROSCIENCES | SCIE | Q3 | — | 142/252 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 104/261 |
| 2011 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 25/48 |
| 2011 | NEUROSCIENCES | SCIE | Q3 | — | 134/244 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 105/261 |
| 2010 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 20/48 |
| 2010 | NEUROSCIENCES | SCIE | Q3 | — | 127/239 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 102/252 |
| 2009 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 21/49 |
| 2009 | NEUROSCIENCES | SCIE | Q2 | — | 107/231 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 77/237 |
| 2008 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 18/47 |
| 2008 | NEUROSCIENCES | SCIE | Q2 | — | 99/221 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 80/219 |
| 2007 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 23/45 |
| 2007 | NEUROSCIENCES | SCIE | Q3 | — | 109/211 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 87/205 |
| 2006 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 27/42 |
| 2006 | NEUROSCIENCES | SCIE | Q3 | — | 123/200 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 96/199 |
| 2005 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 24/42 |
| 2005 | NEUROSCIENCES | SCIE | Q3 | — | 122/200 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 90/193 |
| 2004 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 12/41 |
| 2004 | NEUROSCIENCES | SCIE | Q2 | — | 81/198 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 55/187 |
| 2003 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 18/40 |
| 2003 | NEUROSCIENCES | SCIE | Q2 | — | 88/198 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 58/185 |
| 2002 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 21/39 |
| 2002 | NEUROSCIENCES | SCIE | Q3 | — | 112/197 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 79/188 |
| 2001 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 23/39 |
| 2001 | NEUROSCIENCES | SCIE | Q3 | — | 109/198 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 72/186 |
| 2000 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 18/39 |
| 2000 | NEUROSCIENCES | SCIE | Q3 | — | 105/203 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 66/181 |
| 1999 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 16/38 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 56/175 |
| 1998 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 20/39 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 56/178 |
| 1997 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 20/38 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 61/157 |